Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Aromatase Inhibitor
Related studies linked through entity extraction aliases.
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
- Status
- RECRUITING
- Phase
- PHASE1
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
- Status
- RECRUITING
- Phase
- PHASE2
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
- Status
- COMPLETED
- Phase
- N/A
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
- Status
- UNKNOWN
- Phase
- N/A
Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging
- Status
- COMPLETED
- Phase
- N/A
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
- Status
- COMPLETED
- Phase
- N/A
European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies
- Status
- COMPLETED
- Phase
- N/A
Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone
- Status
- COMPLETED
- Phase
- N/A
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
The Outcome of Two Protocols Used to Prepare Endometrium for Frozen Embryo Transfer
- Status
- COMPLETED
- Phase
- PHASE4
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
- Status
- UNKNOWN
- Phase
- PHASE2
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
- Status
- WITHDRAWN
- Phase
- PHASE1
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3